Ensuring global access to quality medicines: Role of the US pharmacopeia

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1280-1287

  Heyman, Matthew L ^a   Williams, Roger L ^a  

^a UNITED STATES PHARMACOPEIA   (United States)

Author keywords

Formulation; International health; Quality; Regulatory science; Stability; Therapeutic drug monitoring; US Pharmacopeial Convention

Indexed keywords

ILLICIT DRUG; COUNTERFEIT DRUG;

ARTICLE; DEVELOPING COUNTRY; DIET SUPPLEMENTATION; DRUG MANUFACTURE; DRUG PROGRAM; DRUG QUALITY; DRUG STORAGE; DRUG TRAFFIC; EDUCATION PROGRAM; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; INTERNATIONAL COOPERATION; MEDICAL LITERATURE; PHARMACY AND THERAPEUTICS COMMITTEE; UNITED STATES; ANALYSIS; DRUG CONTAMINATION; FRAUD; PREVENTION AND CONTROL; QUALITY CONTROL; STANDARDS;

COUNTERFEIT DRUGS; DIETARY SUPPLEMENTS; DRUG CONTAMINATION; FRAUD; INTERNATIONALITY; QUALITY CONTROL; UNITED STATES;

EID: 79951916298     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22391     Document Type: Article

References (17)

1. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. 2005. The global threat of counterfeit drugs: Why industry and governments must communicate the dangers. PLoS Med 2(4):e100. Accessed October 4, 2010, at.
2. Food and Drug Administration. Counterfeit drug task force report: Combating counterfeit drugs. 2004. Accessed October 4, 2010, at.
3. World Health Organization. Combating counterfeit drugs: A concept paper for effective international cooperation. 2006. Accessed October 4, 2010, at.
4. Kelesidis T, Kelesidis I, Rafailidis PI, Falagas ME. 2007. Counterfeit or substandard antimicrobial drugs: A review of the scientific evidence. J Antimicrob Chemother. DOI: 10.1093/jac/dkm109.
5. Wertheimer AI. 2008. Expert Rev Clin Pharmacol 1(3):333-336. DOI: 10.1586/17512433.1.3.333.
6. USP Drug Quality and Information Program. 2010. Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda. Rockville, Maryland: USP.
7. Shakoor O, Taylor RB, Behrens RH. 1997. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 2:839-845.
8. Abernethy DR, Sheehan C, Griffiths JC, Williams RL. 2009. Adulteration and foods: Compendial approaches to lowering risk. Clin Pharm Ther 85:444-447. DOI: 10.1038/clpt.2008.88.
9. Holloway G, Maheswaran R, Leeks A, Bradby S, Wahab S. 2010. Screening method for ethylene glycol in glycerin-containing products. J Pharm Biomed Anal 51:507-511. PMID: 19782491.
10. Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Shehab N, Ketterer D, Venkataraman G, Kishimoto TK, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, Turabelidze G, Gould Cv, Arduino MJ, Sasisekharan R. 2008. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 359:2674-2684. PMID: 19052120.
11. Anderson L, Higby GJ. 1995. The spirit of voluntarism: A legacy of commitment and contribution: the United States Pharmacopeia 1820-1995. Rockville, Maryland: USP, pp 6-14, 69-72.
12. FDA. 2006. Harvey W. Wiley. Accessed October 4, 2010, at.
13. Federal Food, Drug, and Cosmetic Act §201(j), §§501(b), 502(e).
14. Williams RL, Shah V. 2008. Continuing equivalence: Is there an end to the story? J Generic Med 5(4):297-304.
15. Institute of Medicine Committee for the Study of the Future of Public Health. 1988. The future of public health. Washington, DC: National Academy Press.
16. International Conference on Harmonization. 1996. E6(R1) Guideline for good clinical practice. Accessed October 4, 2010, at.
17. USP. 2010. Promoting the quality of medicines in developing countries. Accessed October 4, 2010, at.